Global Car T Cell Therapy Market (2021 to 2028) - Size, Share, Outlook, and Opportunity Analysis
14 févr. 2022 05h43 HE
|
Research and Markets
Dublin, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The "Car T Cell Therapy Market" report has been added to ResearchAndMarkets.com's offering. Chimeric antigen receptor (CAR) T-cell therapy is a type of...
Monthly information on share capital and company voting rights
11 févr. 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Global CAR T-cell Therapy Market (2021 to 2031) - Industry Analysis, Size, Share, Growth, Trends, and Forecasts
18 janv. 2022 06h58 HE
|
Research and Markets
Dublin, Jan. 18, 2022 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to...
Autolus Therapeutics announces 2022 priorities
10 janv. 2022 07h00 HE
|
Autolus Therapeutics plc
- obe-cel has the potential to transform outcomes for adult ALL patients - Phase 2 FELIX study data expected in 2022 LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:...
Autolus Therapeutics to Present at Conferences During January 2022
05 janv. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research & Developments, 2018-2020 & 2021-2026
17 déc. 2021 07h38 HE
|
Research and Markets
Dublin, Dec. 17, 2021 (GLOBE NEWSWIRE) -- The "Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy" report has been added to ResearchAndMarkets.com's...
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
12 déc. 2021 09h05 HE
|
Sana Biotechnology, Inc
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...
Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition
06 déc. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
15 nov. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
10 nov. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...